—

Caris Life Sciences, Inc. Common Stock (CAI) — the peer cohort

As of 2026-10-27 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Caris Life Sciences, Inc. Common Stock ranks 7 of 7 in its cohort on the Closelooknet composite (61/100) — the cohort is led by BB Biotech AG at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
CAI Caris Life Sciences, Inc. Common Stock 61 98 62 25 ok 1.1%
BION.SW BB Biotech AG 74 65 96 81 info 11.8%
ARGX.BR Argen-X 64 72 76 30 info 15.4%
ONC BeiGene, Ltd. 64 82 65 31 ok 5.8%
UCB.BR UCB SA 64 63 71 54 info 6.8%
ARGX argenx NV ADR 63 67 75 29 info 17.7%
RIGL Rigel Pharmaceuticals Inc 62 94 90 73 ok 3.2%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-27

Quick answers

Who are Caris Life Sciences, Inc. Common Stock's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: BB Biotech AG (BION.SW), Argen-X (ARGX.BR), BeiGene, Ltd. (ONC), UCB SA (UCB.BR), argenx NV ADR (ARGX), Rigel Pharmaceuticals Inc (RIGL).

How does CAI score against its peers?

Caris Life Sciences, Inc. Common Stock's composite reads 61/100, ranking 7 of 7 in its cohort as of 2026-10-27; the cohort's highest composite is BB Biotech AG at 74/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.